胃癌不同组织学分型与微血管密度及相关因子的关系

Relationship of different histological classifications of gastric cancer with microvessel density and related factors

目的:探讨微血管密度(microvascular density,MVD),基质金属蛋白酶-2(matrix metalloproteinase-2,MMP-2)、基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)、血管内皮生长因子(vascular endothelial growth factor,VEGF)、血管内皮生长因子受体1(vascular endothelial growth factor receptor 1,VEGFR1)、血管内皮生长因子受体2(vascular endothelial growth factor receptor 2,VEGFR2)、p53蛋白与胃癌Lauren分型及WHO分型的关系。方法:收集89例胃癌患者的临床数据并将其按照Lauren和WHO标准进行分型。应用单克隆抗体CD34/PAS双重染色评价89例胃癌组织中的微血管密度,免疫组织化学法检测标本中MMP-2、MMP-9、VEGF、VEGFR1、VEGFR2和p53蛋白的表达。结果:在胃癌中,MVD与Lauren分型和WHO分型均无相关性(P>0.05)。Lauren分型与MMP-9、VEGFR1和p53有相关性(P<0.05),与MMP-2、VEGF和VEGFR2无相关性(P>0.05)。WHO分型与各肿瘤相关因子均无相关性(P>0.05)。Lauren分型和WHO分型是胃癌患者独立的预后因素(P<0.05)。结论:对肿瘤相关因子、血管生成与胃癌发生、发展过程的研究,可能为不同组织学分型的胃癌患者提供新的治疗方法。

Objective：To investigate the correlations of Lauren classification and world health organization （WHO） classification of gastric cancer （GC） with microvascular density （MVD）, matrix metalloproteinase-2 （MMP-2）, matrix metalloproteinase-9 （MMP-9）, vascular endothelial growth factor （VEGF）, vascular endothelial growth factor receptor 1 （VEGFR1）, vascular endothelial growth factor receptor 2 （VEGFR2）, and p53. Methods：The clinical data of 89 patients with GC were collected. The collected specimens were categorized on the basis of Lauren classification and WHO classification. CD34/periodic acid-Schiff （PAS） double staining was performed to validate MVD. Immunohistochemistry was conducted to investigate the expression levels of MMP-2, MMP-9, VEGF, VEGFR1, VEGFR2, and p53. Results：MVD was not correlated with Lauren classification or WHO classification （P＆gt;0.05）. Lauren typing was associated with the expression levels of MMP-9, VEGFR1, and p53 （P＆lt;0.05）. WHO classification was not related to any of the factors （P〉0.05）. Cox proportional hazards model revealed that Lauren classification and WHO classification were the prognostic factors of overall survival （P〈0.05）. Conclusion：This research on tumor related factors, angiogenesis, and different classifications of GC may provide new methods to treat this disease.